Compare CLMT & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLMT | PBLS |
|---|---|---|
| Founded | 1916 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2024 | 2026 |
| Metric | CLMT | PBLS |
|---|---|---|
| Price | $59.01 | $41.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $28.65 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 489.4K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.39 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,137,100,000.00 | N/A |
| Revenue This Year | $3.94 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.42 | $25.56 |
| 52 Week High | $59.67 | $42.49 |
| Indicator | CLMT | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 75.69 | 62.12 |
| Support Level | $30.74 | $37.77 |
| Resistance Level | N/A | $41.34 |
| Average True Range (ATR) | 2.31 | 2.26 |
| MACD | 0.32 | -0.13 |
| Stochastic Oscillator | 92.77 | 80.55 |
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.